Jiaoti Huang

A probe of the maximum energetics of fast radio bursts through a prolific repeating source

Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer

SCORT–Cas13d Nanotherapy Precisely Targets the ‘Undruggable’ Transcription Factor HoxB13 in Metastatic Prostate Cancer In Vivo

Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone

Single-dose cathepsin L CRISPR nanotherapy mitigates PASC-like lung damage in hamsters

UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas

Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies

Abstract 6574: UCHL1 is a molecular indicator and a therapeutic target for neuroendocrine carcinomas

Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma

Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation

The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity

Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer

The DNA methylation landscape of advanced prostate cancer

The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer

Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance

LIN28B promotes the development of neuroendocrine prostate cancer

Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies

Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer

Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer

Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage

Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13

Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses

A Human Adult Stem Cell Signature Marks Aggressive Variants across Epithelial Cancers

SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression